Released May 9, 2024, after the close
10-Q filed May 9, 2024, 39 days after period end · 0000950170-24-057213
Q1 2024 · 10-Q
Revenue$45.54M$45.54M +81.3% vs Q1 2023+61.6% vs Q4 2023
Net Income-$32.16M-$32.16M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.27-$0.27 N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit$24,188,000+97.0%
Operating Income-$60,182,000N/M
Operating Cash Flow-$62,476,000N/M
Free Cash Flowderived-$63,257,000N/M
Margins · derived
Gross margin53.1%+4.2 pt vs Q1 2023
Operating margin-132.2%−66.1 pt vs Q1 2023
Net margin-70.6%−3.6 pt vs Q1 2023
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $45.54M | $25.12M | $26.50M | $32.79M |
| Net Income | -$32.16M | -$16.84M | -$76.29M | -$18.82M |
| EPS Diluted | -$0.27 | -$0.21 | -$0.99 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR